sarpogrelate has been researched along with Anterior Choroidal Artery Infarction in 4 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported." | 9.14 | Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009) |
| "In total, 1510 patients with recent cerebral infarction (1 week to 6 months after onset) were randomly assigned to receive either sarpogrelate (100 mg TID) or aspirin (81 mg/d)." | 9.13 | Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. ( Fukuuchi, Y; Gotoh, F; Handa, S; Hayashi, K; Hirai, S; Kobayashi, S; Kondo, K; Nishimaru, K; Otomo, E; Sawada, T; Shinohara, Y; Terashi, A; Tohgi, H; Uchiyama, S; Yamaguchi, T, 2008) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported." | 5.14 | Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009) |
| "In total, 1510 patients with recent cerebral infarction (1 week to 6 months after onset) were randomly assigned to receive either sarpogrelate (100 mg TID) or aspirin (81 mg/d)." | 5.13 | Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. ( Fukuuchi, Y; Gotoh, F; Handa, S; Hayashi, K; Hirai, S; Kobayashi, S; Kondo, K; Nishimaru, K; Otomo, E; Sawada, T; Shinohara, Y; Terashi, A; Tohgi, H; Uchiyama, S; Yamaguchi, T, 2008) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shaikh, Q | 1 |
| Kamal, AK | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Shinohara, Y | 2 |
| Nishimaru, K | 2 |
| Sawada, T | 1 |
| Terashi, A | 1 |
| Handa, S | 1 |
| Hirai, S | 1 |
| Hayashi, K | 1 |
| Tohgi, H | 1 |
| Fukuuchi, Y | 1 |
| Uchiyama, S | 1 |
| Yamaguchi, T | 1 |
| Kobayashi, S | 1 |
| Kondo, K | 1 |
| Otomo, E | 1 |
| Gotoh, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial[NCT00129805] | Phase 3 | 1,510 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for sarpogrelate and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
Topics: Aged; Aspirin; Cerebral Infarction; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-U | 2009 |
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Double-Blind Method; Female; Humans; Incide | 2008 |
2 other studies available for sarpogrelate and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Sarpogrelate- another new antiplatelet agent?
Topics: Aspirin; Cerebral Infarction; China; Female; Humans; Japan; Male; Platelet Aggregation Inhibitors; R | 2012 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |